By Billy Candra 
In a significant paradigm shift for oncology, new research from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has unveiled a complex and previously misunderstood role for regulatory T (Treg) cells in colorectal cancer. For decades, the presence of a high number of Treg cells in solid tumors has been consistently linked to poorer patient outcomes across a wide spectrum of cancers. These specialized immune cells are known to act as the immune system’s natural "brakes," suppressing other immune responses and thereby hindering the body’s ability to mount an effective attack against cancerous cells. However, colorectal cancer has long stood as a perplexing anomaly, where, counterintuitively, a higher density of Treg cells within tumors often correlated with prolonged survival for patients. This puzzling discrepancy has confounded researchers, leading to an incomplete understanding of immune responses in this prevalent malignancy.
The new study, published in the prestigious scientific journal Immunity, provides the definitive explanation for this long-standing paradox. The core discovery fundamentally redefines our understanding of Treg cells, revealing that these immune regulators are not a uniform population but rather comprise distinct subtypes with opposing effects on tumor growth. This nuanced understanding has profound implications, not only for improving immunotherapy strategies for the majority of colorectal cancer patients but also potentially for other cancers arising in "barrier tissues" such as the skin, stomach lining, mouth, and throat.
Unraveling the Colorectal Cancer Conundrum
Colorectal cancer (CRC) remains a formidable health challenge globally. According to the American Cancer Society, it is the second leading cause of cancer-related death when men and women are combined, responsible for an estimated 53,090 deaths in the United States in 2024, with approximately 153,020 new cases diagnosed annually. The disease’s varied clinical presentations and responses to treatment underscore the urgent need for more effective and targeted therapies.
The traditional view held that Treg cells, by maintaining "immune tolerance" – preventing the immune system from attacking healthy tissues, beneficial microbes, and harmless substances – were largely detrimental in the context of cancer. Their suppressive function was thought to consistently dampen anti-tumor immunity, allowing cancer cells to evade detection and destruction. This general principle applied to most solid tumors, where an abundance of Tregs often signified a hostile microenvironment for immune-mediated tumor eradication.
However, the consistent observation in colorectal cancer, where higher Treg infiltration was paradoxically associated with better prognosis, presented a major hurdle to developing universal immunotherapy approaches. This MSK study has now cracked this code, demonstrating that the sheer number of Treg cells is less important than which kind of Treg cells are present within the tumor microenvironment.
A Decades-Long Scientific Quest Culminates in Breakthrough
This groundbreaking research builds upon more than two decades of pioneering work by Dr. Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK, and a distinguished Howard Hughes Medical Institute Investigator. Dr. Rudensky is widely recognized as one of the world’s foremost authorities on regulatory T cells. His foundational research played a crucial role in establishing the very concept of Treg cells and their indispensable role in maintaining immune homeostasis and preventing autoimmune diseases. Over the years, his laboratory has systematically uncovered the intricate mechanisms governing Treg cell development, function, and their multifaceted influence on various disease states, including cancer.
The current study was a collaborative effort, led by first authors Dr. Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dr. Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Dr. Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Dr. Christina Leslie, PhD, who also served as the study’s other senior author. Their combined expertise in immunology, oncology, and computational biology was critical to dissecting the complex cellular interactions within the tumor microenvironment.
Identifying Two Distinct Treg Subtypes with Opposing Roles
The MSK team focused its investigation on the most common form of colorectal cancer, specifically microsatellite stable (MSS) tumors with proficient mismatch repair (MMRp). This subtype accounts for a substantial 80% to 85% of all colorectal cancers and is notoriously difficult to treat with current checkpoint inhibitor immunotherapies. Unlike their microsatellite unstable (MSI-H) counterparts, which often respond favorably to immunotherapy due to their high mutational burden, MSS-MMRp tumors typically exhibit a "cold" immune environment, rendering them largely refractory to these advanced treatments. Understanding the immune dynamics in MSS-MMRp CRC is thus paramount for improving outcomes for the vast majority of patients.
To explore the unique immune landscape of common colorectal cancers, the researchers utilized a sophisticated mouse model developed at MSK. This model faithfully recapitulates the genetic alterations, disease progression, and immune characteristics observed in human colorectal tumors, providing a robust platform for mechanistic studies. Through meticulous experimentation, they discovered that tumor-associated Treg cells could be definitively categorized into two primary groups based on their cytokine production profile: those that produce the signaling molecule interleukin-10 (IL-10), and those that do not.
The selective removal of each of these Treg groups in a series of detailed experiments revealed starkly different effects on tumor growth:
-
IL-10-positive Treg cells: These cells were found to be beneficial, actively slowing tumor progression. Their mechanism of action involves reducing the activity of Th17 cells, another type of immune cell that produces interleukin-17 (IL-17). IL-17 is known to act as a growth signal for tumors, promoting their proliferation and survival. These protective IL-10-positive Treg cells were more commonly observed in healthy tissue adjacent to the tumor, suggesting a role in maintaining local tissue homeostasis. Critically, when these beneficial IL-10-positive Treg cells were experimentally depleted, tumors in the mouse models grew significantly faster, underscoring their protective role.
-
IL-10-negative Treg cells: In stark contrast, these cells exerted a detrimental effect on tumor control. They were found to suppress powerful immune effector cells, particularly CD8+ T cells, which are renowned for their direct cancer-killing capabilities. This harmful subtype was predominantly located within the tumor mass itself, suggesting a direct role in creating an immunosuppressive tumor microenvironment. The elimination of these IL-10-negative Treg cells resulted in a notable reduction in tumor size, confirming their role in fueling tumor growth by dampening anti-tumor immunity.
Translational Validation: Patient Data Confirms Dual Role
The researchers rigorously validated these groundbreaking findings using human colorectal cancer tumor samples. Analysis of these clinical specimens confirmed the presence of two distinct populations of IL-10-positive and IL-10-negative Treg cells in patients. Further bolstering their conclusions, the team analyzed outcomes for over 100 colorectal cancer patients. The results were compelling: patients with higher levels of the beneficial IL-10-positive Treg cells exhibited significantly longer survival, while those whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells experienced poorer clinical outcomes.
"This research unequivocally demonstrates the critical importance of these positive cells," states Dr. Huang. "It highlights a crucial need to develop therapeutic strategies that can selectively eliminate the harmful Tregs while meticulously preserving the helpful ones. A blanket approach to Treg depletion could be counterproductive in colorectal cancer." This nuanced understanding paves the way for a more targeted and effective approach to immunotherapy, moving beyond the simplistic notion of "good" or "bad" immune cells.
CCR8: A Promising New Therapeutic Target
The identification of these functionally distinct Treg subtypes has immediately suggested a promising avenue for improving treatment for the majority of colorectal cancer patients. The MSK researchers made another pivotal discovery: the harmful IL-10-negative Treg cells express high levels of a specific protein called CCR8 on their surface. These are precisely the cells that suppress the immune response and are predominantly found within the tumor core.
This finding builds upon earlier foundational work from Dr. Rudensky’s lab, notably led by breast cancer surgeon Dr. George Plitas, MD. That research previously demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human cancers. This convergence of findings across different cancer types suggests that CCR8 could serve as a universal biomarker and therapeutic target for selectively eliminating harmful Treg populations. The original research suggested that antibodies designed to target and deplete CCR8-expressing cells could effectively remove these detrimental Treg cells, thereby unleashing the immune system to attack tumors more effectively, all while leaving the beneficial Treg cells intact.
"This innovative idea of using CCR8-depleting antibodies, a concept pioneered right here at MSK, has rapidly become the primary focus of global efforts to bring regulatory T cell-based immunotherapy into clinical practice," Dr. Rudensky emphasizes. Multiple clinical trials are currently underway at MSK and other leading institutions worldwide, investigating this novel approach both as a standalone therapy and in combination with existing immunotherapies. The compelling data from the current colorectal cancer study provides strong evidence and significantly strengthens the rationale for integrating this CCR8-targeting strategy into treatment protocols for CRC and potentially a broader range of solid tumors.
Broader Implications: Similar Immune Patterns in Other Cancers
Recognizing the potential for wider applicability, the research team extended their analysis to a comprehensive dataset of T cells derived from 16 different cancer types. Their investigation revealed that similar divisions between IL-10-positive and IL-10-negative Treg cells were present in several other malignancies, particularly those affecting barrier tissues such as the skin, and the linings of the mouth, throat, and stomach.
"What these tissues share in common is a constant exposure to microbes and environmental stresses, necessitating a critical role for immune cells in their continuous defense and repair," explains Dr. Mitra, who spearheaded the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This shared immunological environment suggests that the immune regulation mechanisms identified in colorectal cancer may be fundamental to these other barrier tissues as well. Consequently, therapies designed to selectively remove IL-10-negative Treg cells in colorectal cancer could also prove effective against these other cancers that arise in analogous anatomical sites. This opens the door for a more unified approach to treating a broader spectrum of cancers, moving away from a purely organ-specific treatment paradigm.
Metastatic Disease: A Distinct Immune Balance
The researchers also explored the immune landscape in colorectal cancer that had metastasized, specifically to the liver. Here, they observed a notably different immune pattern. In these metastatic tumors, the harmful IL-10-negative Treg cells significantly outnumbered the beneficial IL-10-positive cells. Unlike primary tumors, where selective targeting is crucial, the complete removal of all Treg cells in this metastatic context actually led to a shrinkage of the tumors. This finding highlights the critical need for treatment strategies that are not only tailored to the specific tissue involved but also to the stage of the disease. The immune microenvironment in metastatic lesions can differ substantially from primary tumors, necessitating a flexible and adaptive therapeutic approach.
Towards Precision Immunotherapy
The findings from Memorial Sloan Kettering Cancer Center represent a significant leap forward in our understanding of tumor immunology and promise to redefine treatment paradigms for colorectal cancer. By dissecting the heterogeneous nature of Treg cells, the researchers have illuminated a path toward more precise and effective immunotherapies. Instead of broad-stroke immune modulation, the future of cancer treatment may lie in selectively fine-tuning the immune response, eliminating detrimental components while preserving or even enhancing beneficial ones. This approach holds the potential to transform outcomes for millions of patients battling colorectal cancer and possibly many other forms of cancer previously deemed unresponsive to immunotherapy.
The ongoing clinical trials evaluating CCR8-depleting antibodies are a direct consequence of this pioneering research, underscoring the rapid translation of fundamental scientific discovery into tangible therapeutic opportunities. As our understanding of the tumor microenvironment continues to evolve, studies like this pave the way for a new era of personalized oncology, where treatments are meticulously designed to exploit the unique immunological vulnerabilities of each patient’s cancer.
Authors, Funding, and Disclosures
Additional authors contributing to this impactful study include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. The Integrated Genomics Operation and the Single Cell Research Initiative at MSK were instrumental in providing key support and resources for the research.
This study received generous funding from multiple sources, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-José Kravis Fellowship in Quantitative Biology.
In the interest of full transparency, Dr. Rudensky serves on several scientific advisory boards and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member for Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Furthermore, Dr. Rudensky and Dr. Plitas are recognized as inventors on patents and patent applications held by MSK, which are related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies developed against CCR8. These disclosures highlight potential conflicts of interest but also underscore the direct translational impact of their scientific contributions.
